Nadine Zakkak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadine Zakkak has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Georgios Lyratzopoulos
Epidemiology of Cancer Healthcare and Outcomes Group, University College London, London, UK
7 shared publications - Becky White
Epidemiology of Cancer Healthcare and Outcomes Group, Department of Behavioural Science, Institute of Epidemiology and Health Care, University College London, London, UK
4 shared publications - Matthew Barclay
Affiliation ECHO (Epidemiology of Cancer Healthcare & Outcomes), Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, UCL (University College London), London, United Kingdom
4 shared publications - Meena Rafiq
Epidemiology of Cancer Healthcare & Outcomes (ECHO) Group, Department of Behavioural Science, Institute of Epidemiology and Health Care (IEHC), UCL, London, UK
4 shared publications - Arturo Gonzalez-Izquierdo
Department of Applied Health Sciences, University of Birmingham, Birmingham, UK
3 shared publications - Cristina Renzi
Epidemiology of Cancer Healthcare and Outcomes Group, University College London, London, UK
3 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (8) , e1005182
Frequency and prognostic outcomes of emergency diagnosis in 13 non-neoplastic conditions in England: A population-based cohort study using linked electronic health records of 1.7 million patients
Background: In patients with cancer, diagnosis through or soon after the use of emergency hospital care (‘emergency diagnosis’) is associated with advanced disease and poor prognosis. The varied and complex reasons for emergency diagnoses—including rapid disease progression, patient factors, and system delays—are unlikely to be unique to cancer. However, little is known about the frequency and prognostic outcomes of emergency diagnosis in other conditions. We aimed to document the frequency of emergency diagnoses across various non-neoplastic conditions and examine the association of emergency diagnosis with clinical outcomes. Methods and findings: We analysed records from linked primary care, secondary care, and death data (Clinical Practice Research Datalink (CPRD), Hospital Episode Statistics, Office for National Statistics) for 1,701,154 patients with one of 13 exemplar conditions (axial spondyloarthritis, coeliac disease, coronary/ischaemic heart disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), Lyme disease, multiple sclerosis (MS), Parkinson’s disease, polycystic ovary syndrome, rheumatoid arthritis, schizophrenia, subacute bacterial endocarditis, and tuberculosis) in England between 1999 and 2019. We examined the percentage of patients diagnosed as an emergency and compared their mortality and time in hospital in the year post-diagnosis with patients who were not diagnosed as an emergency. Emergency diagnosis occurred in at least 20% of patients for 9 out of 13 conditions in our sample, including more than 30% of patients with Parkinson’s disease and 35% of patients with COPD. For 9 out of 13 conditions, there was a substantial increase (at least +10% difference) in 1-year mortality in patients diagnosed as an emergency versus patients who were not diagnosed as an emergency. After adjusting for age and year of diagnosis, deprivation, comorbidity burden, and the healthcare setting in which the diagnosis was made, patients diagnosed as an emergency were typically much more likely to die within one year. This association held even in conditions with generally good prognosis, such as coeliac disease (adjusted odds ratio 7.53, 95% CI [5.64, 10.1], women) and IBD (adjusted odds ratio 5.99, 95% CI [5.30, 6.78], men). Similarly large differences were observed for time in hospital in the year post-diagnosis by emergency diagnosis status. For example, adjusted rate ratios of 8.76 (95% CI [6.52, 11.8]) for men with coeliac disease, and 5.59 (95%CI [2.57, 12.2]) for women diagnosed with Lyme disease. The findings were consistent across two subsets of CPRD data (Aurum, GOLD). Analyses of patients with five supplementary cancer sites (brain, colon, lung, pancreas, and ovary) produced findings concordant with prior literature, supporting the validity of the study methods. The main study limitation is the assumption of accurate recording of diagnoses in health records. Conclusions: Emergency diagnosis is common and associated with worse clinical outcomes in a wide range of conditions with diverse aetiology. Further research and investment to reduce the number of emergency diagnoses is needed, particularly for diseases where diagnosis in community settings should be expected (e.g., rheumatoid arthritis and COPD), and conditions such as coeliac disease, IBD, and MS, where emergency diagnosis is associated with particularly poor outcomes.
- 25 August 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (8) , e1005182
Open AccessFrequency and prognostic outcomes of emergency diagnosis in 13 non-neoplastic conditions in England: A population-based cohort study using linked electronic health records of 1.7 million patients
Background: In patients with cancer, diagnosis through or soon after the use of emergency hospital care (‘emergency diagnosis’) is associated with advanced disease and poor prognosis. The varied and complex reasons for emergency diagnoses—including rapid disease progression, patient factors, and system delays—are unlikely to be unique to cancer. However, little is known about the frequency and prognostic outcomes of emergency diagnosis in other conditions. We aimed to document the frequency of emergency diagnoses across various non-neoplastic conditions and examine the association of emergency diagnosis with clinical outcomes. Methods and findings: We analysed records from linked primary care, secondary care, and death data (Clinical Practice Research Datalink (CPRD), Hospital Episode Statistics, Office for National Statistics) for 1,701,154 patients with one of 13 exemplar conditions (axial spondyloarthritis, coeliac disease, coronary/ischaemic heart disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), Lyme disease, multiple sclerosis (MS), Parkinson’s disease, polycystic ovary syndrome, rheumatoid arthritis, schizophrenia, subacute bacterial endocarditis, and tuberculosis) in England between 1999 and 2019. We examined the percentage of patients diagnosed as an emergency and compared their mortality and time in hospital in the year post-diagnosis with patients who were not diagnosed as an emergency. Emergency diagnosis occurred in at least 20% of patients for 9 out of 13 conditions in our sample, including more than 30% of patients with Parkinson’s disease and 35% of patients with COPD. For 9 out of 13 conditions, there was a substantial increase (at least +10% difference) in 1-year mortality in patients diagnosed as an emergency versus patients who were not diagnosed as an emergency. After adjusting for age and year of diagnosis, deprivation, comorbidity burden, and the healthcare setting in which the diagnosis was made, patients diagnosed as an emergency were typically much more likely to die within one year. This association held even in conditions with generally good prognosis, such as coeliac disease (adjusted odds ratio 7.53, 95% CI [5.64, 10.1], women) and IBD (adjusted odds ratio 5.99, 95% CI [5.30, 6.78], men). Similarly large differences were observed for time in hospital in the year post-diagnosis by emergency diagnosis status. For example, adjusted rate ratios of 8.76 (95% CI [6.52, 11.8]) for men with coeliac disease, and 5.59 (95%CI [2.57, 12.2]) for women diagnosed with Lyme disease. The findings were consistent across two subsets of CPRD data (Aurum, GOLD). Analyses of patients with five supplementary cancer sites (brain, colon, lung, pancreas, and ovary) produced findings concordant with prior literature, supporting the validity of the study methods. The main study limitation is the assumption of accurate recording of diagnoses in health records. Conclusions: Emergency diagnosis is common and associated with worse clinical outcomes in a wide range of conditions with diverse aetiology. Further research and investment to reduce the number of emergency diagnoses is needed, particularly for diseases where diagnosis in community settings should be expected (e.g., rheumatoid arthritis and COPD), and conditions such as coeliac disease, IBD, and MS, where emergency diagnosis is associated with particularly poor outcomes.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Risk of cancer following presentation with new-onset atrial fibrillation using data from UK national databases
Aims: Atrial fibrillation (AF) and cancer are both highly prevalent conditions and are known to be associated. Our aim was to identify predictors and develop models for all cancer types, in men and women, and for the four most common cancer types in the AF population using linked primary and secondary care data from the UK. Methods and results: We included 163 549 patients diagnosed with AF between January 1998 and May 2016, and no previous history of cancer. Following TRIPOD methodology, we developed a ridge-penalized multivariable logistic regression model to predict 1-year cancer incidence after AF diagnosis, using 70% of the data for derivation and 30% for validation. Age was associated with an increased risk across all cancer types. Socioeconomic deprivation, smoking, excessive alcohol intake, family history of cancer, chronic kidney disease, anaemia, and several cancer-related symptoms and clinical signs (e.g. rectal bleeding, loss of appetite) were associated with an increased risk in one or more cancer types. The prediction models showed moderate-to-good discrimination in the validation set, with c-statistic of 0.69 (0.68–0.70) for all cancer in men, 0.63 (0.62–0.65) for all cancer in women, 0.70 (0.68–0.73) for lung cancer, 0.70 (0.66–0.73) for colorectal cancer, 0.59 (0.53–0.65) for breast cancer, and 0.78 (0.72–0.84) for prostate cancer. Conclusion: Most of the identified potential risk factors for cancer in the AF population are also associated with cardiovascular disease. The 1-year cancer prediction models showed moderate to good predictive performance and may help improve the management of patients with AF.
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessRisk of cancer following presentation with new-onset atrial fibrillation using data from UK national databases
Aims: Atrial fibrillation (AF) and cancer are both highly prevalent conditions and are known to be associated. Our aim was to identify predictors and develop models for all cancer types, in men and women, and for the four most common cancer types in the AF population using linked primary and secondary care data from the UK. Methods and results: We included 163 549 patients diagnosed with AF between January 1998 and May 2016, and no previous history of cancer. Following TRIPOD methodology, we developed a ridge-penalized multivariable logistic regression model to predict 1-year cancer incidence after AF diagnosis, using 70% of the data for derivation and 30% for validation. Age was associated with an increased risk across all cancer types. Socioeconomic deprivation, smoking, excessive alcohol intake, family history of cancer, chronic kidney disease, anaemia, and several cancer-related symptoms and clinical signs (e.g. rectal bleeding, loss of appetite) were associated with an increased risk in one or more cancer types. The prediction models showed moderate-to-good discrimination in the validation set, with c-statistic of 0.69 (0.68–0.70) for all cancer in men, 0.63 (0.62–0.65) for all cancer in women, 0.70 (0.68–0.73) for lung cancer, 0.70 (0.66–0.73) for colorectal cancer, 0.59 (0.53–0.65) for breast cancer, and 0.78 (0.72–0.84) for prostate cancer. Conclusion: Most of the identified potential risk factors for cancer in the AF population are also associated with cardiovascular disease. The 1-year cancer prediction models showed moderate to good predictive performance and may help improve the management of patients with AF.
- Open Access
- 26 December 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (750) , e57-e67
Underlying disease risk among patients with fatigue: a population-based cohort study in primary care
Background: Presenting to primary care with fatigue is associated with a wide range of conditions, including cancer, although their relative likelihood is unknown. Aim: To quantify associations between new-onset fatigue presentation and subsequent diagnosis of various diseases, including cancer. Design and setting: A cohort study of patients presenting in English primary care with new-onset fatigue during 2007–2017 (the fatigue group) compared with patients who presented without fatigue (the non-fatigue group), using Clinical Practice Research Datalink data linked to hospital episodes and national cancer registration data. Method: The excess short-term incidence of 237 diseases in patients who presented with fatigue compared with those who did not present with fatigue is described. Disease-specific 12-month risk by sex was modelled and the age-adjusted risk calculated. Results: The study included 304 914 people in the fatigue group and 423 671 in the non-fatigue group. In total, 127 of 237 diseases studied were more common in men who presented with fatigue than in men who did not, and 151 were more common in women who presented with fatigue. Diseases that were most strongly associated with fatigue included: depression; respiratory tract infections; insomnia and sleep disturbances; and hypo/hyperthyroidism (women only). By age 80 years, cancer was the third most common disease and had the fourth highest absolute excess risk in men who presented with fatigue (fatigue group: 7.01%, 95% confidence interval [CI] = 6.54 to 7.51; non-fatigue group: 3.36%, 95% CI = 3.08 to 3.67; absolute excess risk 3.65%). In women, cancer remained relatively infrequent; by age 80 years it had the thirteenth highest excess risk in patients who presented with fatigue. Conclusion: This study ranked the likelihood of possible diagnoses in patients who presented with fatigue, to inform diagnostic guidelines and doctors’ decisions. Age-specific findings support recommendations to prioritise cancer investigation in older men (aged ≥70 years) with fatigue, but not in women at any age, based solely on the presence of fatigue.
- 26 December 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (750) , e57-e67
Open AccessUnderlying disease risk among patients with fatigue: a population-based cohort study in primary care
Background: Presenting to primary care with fatigue is associated with a wide range of conditions, including cancer, although their relative likelihood is unknown. Aim: To quantify associations between new-onset fatigue presentation and subsequent diagnosis of various diseases, including cancer. Design and setting: A cohort study of patients presenting in English primary care with new-onset fatigue during 2007–2017 (the fatigue group) compared with patients who presented without fatigue (the non-fatigue group), using Clinical Practice Research Datalink data linked to hospital episodes and national cancer registration data. Method: The excess short-term incidence of 237 diseases in patients who presented with fatigue compared with those who did not present with fatigue is described. Disease-specific 12-month risk by sex was modelled and the age-adjusted risk calculated. Results: The study included 304 914 people in the fatigue group and 423 671 in the non-fatigue group. In total, 127 of 237 diseases studied were more common in men who presented with fatigue than in men who did not, and 151 were more common in women who presented with fatigue. Diseases that were most strongly associated with fatigue included: depression; respiratory tract infections; insomnia and sleep disturbances; and hypo/hyperthyroidism (women only). By age 80 years, cancer was the third most common disease and had the fourth highest absolute excess risk in men who presented with fatigue (fatigue group: 7.01%, 95% confidence interval [CI] = 6.54 to 7.51; non-fatigue group: 3.36%, 95% CI = 3.08 to 3.67; absolute excess risk 3.65%). In women, cancer remained relatively infrequent; by age 80 years it had the thirteenth highest excess risk in patients who presented with fatigue. Conclusion: This study ranked the likelihood of possible diagnoses in patients who presented with fatigue, to inform diagnostic guidelines and doctors’ decisions. Age-specific findings support recommendations to prioritise cancer investigation in older men (aged ≥70 years) with fatigue, but not in women at any age, based solely on the presence of fatigue.
- Open Access
- 14 October 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (754) , e300-e305
Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit
Background: Prostate-specific antigen (PSA) is used in primary care for prostate cancer detection, either for symptomatic assessment or asymptomatic testing following an informed decision. Aim: To estimate the proportion of patients with prostate cancer who were diagnosed following asymptomatic PSA testing, and the patient and practice factors influencing this route. Design and setting: The 2018 English National Cancer Diagnosis Audit (NCDA) data were analysed, with linkage to the National Cancer Registration and Analysis Service, practice-level Quality and Outcomes Framework (QOF), and GP Patient Survey (GPPS) data. All 2018 NCDA patients with a diagnosis of prostate cancer were included ( n = 9837). Method: Patients with recorded biomarker testing and no recorded symptoms before diagnosis were classified as having asymptomatic PSA-detected prostate cancer. Patient (age, ethnicity, deprivation, and comorbidities) and practice (geographical location, area deprivation, list size, urgent suspected cancer referral rate, QOF outcomes, and GPPS results) factors were analysed for association with asymptomatic PSA testing using mixed-effects logistic regression models. Results: In total, 1884 out of 9837 (19.2%) patients with prostate cancer were detected following asymptomatic PSA testing, 982 (52.1%) of whom were aged 50–69 years. Younger age, non-White ethnicity, lower deprivation, and lower comorbidity count were associated with an increased likelihood of diagnosis following asymptomatic PSA testing. There was a 13-fold variation between practices in the odds of detecting prostate cancer through asymptomatic PSA testing, without clear explanatory practice-level factors. Conclusion: One in five patients with prostate cancer in England are diagnosed after asymptomatic PSA testing in primary care, with large variation in asymptomatic PSA detection between practices.
- 14 October 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (754) , e300-e305
Open AccessFactors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit
Background: Prostate-specific antigen (PSA) is used in primary care for prostate cancer detection, either for symptomatic assessment or asymptomatic testing following an informed decision. Aim: To estimate the proportion of patients with prostate cancer who were diagnosed following asymptomatic PSA testing, and the patient and practice factors influencing this route. Design and setting: The 2018 English National Cancer Diagnosis Audit (NCDA) data were analysed, with linkage to the National Cancer Registration and Analysis Service, practice-level Quality and Outcomes Framework (QOF), and GP Patient Survey (GPPS) data. All 2018 NCDA patients with a diagnosis of prostate cancer were included ( n = 9837). Method: Patients with recorded biomarker testing and no recorded symptoms before diagnosis were classified as having asymptomatic PSA-detected prostate cancer. Patient (age, ethnicity, deprivation, and comorbidities) and practice (geographical location, area deprivation, list size, urgent suspected cancer referral rate, QOF outcomes, and GPPS results) factors were analysed for association with asymptomatic PSA testing using mixed-effects logistic regression models. Results: In total, 1884 out of 9837 (19.2%) patients with prostate cancer were detected following asymptomatic PSA testing, 982 (52.1%) of whom were aged 50–69 years. Younger age, non-White ethnicity, lower deprivation, and lower comorbidity count were associated with an increased likelihood of diagnosis following asymptomatic PSA testing. There was a 13-fold variation between practices in the odds of detecting prostate cancer through asymptomatic PSA testing, without clear explanatory practice-level factors. Conclusion: One in five patients with prostate cancer in England are diagnosed after asymptomatic PSA testing in primary care, with large variation in asymptomatic PSA detection between practices.
- Open Access
- 31 July 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (750) , e57-e67
Underlying disease risk among patients with fatigue: a population-based cohort study in primary care
Background: Presenting to primary care with fatigue is associated with a wide range of conditions, including cancer, although their relative likelihood is unknown. Aim: To quantify associations between new-onset fatigue presentation and subsequent diagnosis of various diseases, including cancer. Design and setting: A cohort study of patients presenting in English primary care with new-onset fatigue during 2007–2017 (the fatigue group) compared with patients who presented without fatigue (the non-fatigue group), using Clinical Practice Research Datalink data linked to hospital episodes and national cancer registration data. Method: The excess short-term incidence of 237 diseases in patients who presented with fatigue compared with those who did not present with fatigue is described. Disease-specific 12-month risk by sex was modelled and the age-adjusted risk calculated. Results: The study included 304 914 people in the fatigue group and 423 671 in the non-fatigue group. In total, 127 of 237 diseases studied were more common in men who presented with fatigue than in men who did not, and 151 were more common in women who presented with fatigue. Diseases that were most strongly associated with fatigue included: depression; respiratory tract infections; insomnia and sleep disturbances; and hypo/hyperthyroidism (women only). By age 80 years, cancer was the third most common disease and had the fourth highest absolute excess risk in men who presented with fatigue (fatigue group: 7.01%, 95% confidence interval [CI] = 6.54 to 7.51; non-fatigue group: 3.36%, 95% CI = 3.08 to 3.67; absolute excess risk 3.65%). In women, cancer remained relatively infrequent; by age 80 years it had the thirteenth highest excess risk in patients who presented with fatigue. Conclusion: This study ranked the likelihood of possible diagnoses in patients who presented with fatigue, to inform diagnostic guidelines and doctors’ decisions. Age-specific findings support recommendations to prioritise cancer investigation in older men (aged ≥70 years) with fatigue, but not in women at any age, based solely on the presence of fatigue.
- 31 July 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (750) , e57-e67
Open AccessUnderlying disease risk among patients with fatigue: a population-based cohort study in primary care
Background: Presenting to primary care with fatigue is associated with a wide range of conditions, including cancer, although their relative likelihood is unknown. Aim: To quantify associations between new-onset fatigue presentation and subsequent diagnosis of various diseases, including cancer. Design and setting: A cohort study of patients presenting in English primary care with new-onset fatigue during 2007–2017 (the fatigue group) compared with patients who presented without fatigue (the non-fatigue group), using Clinical Practice Research Datalink data linked to hospital episodes and national cancer registration data. Method: The excess short-term incidence of 237 diseases in patients who presented with fatigue compared with those who did not present with fatigue is described. Disease-specific 12-month risk by sex was modelled and the age-adjusted risk calculated. Results: The study included 304 914 people in the fatigue group and 423 671 in the non-fatigue group. In total, 127 of 237 diseases studied were more common in men who presented with fatigue than in men who did not, and 151 were more common in women who presented with fatigue. Diseases that were most strongly associated with fatigue included: depression; respiratory tract infections; insomnia and sleep disturbances; and hypo/hyperthyroidism (women only). By age 80 years, cancer was the third most common disease and had the fourth highest absolute excess risk in men who presented with fatigue (fatigue group: 7.01%, 95% confidence interval [CI] = 6.54 to 7.51; non-fatigue group: 3.36%, 95% CI = 3.08 to 3.67; absolute excess risk 3.65%). In women, cancer remained relatively infrequent; by age 80 years it had the thirteenth highest excess risk in patients who presented with fatigue. Conclusion: This study ranked the likelihood of possible diagnoses in patients who presented with fatigue, to inform diagnostic guidelines and doctors’ decisions. Age-specific findings support recommendations to prioritise cancer investigation in older men (aged ≥70 years) with fatigue, but not in women at any age, based solely on the presence of fatigue.
- Open Access
- 30 July 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (7) , e1004426
Predictive value of abnormal blood tests for detecting cancer in primary care patients with nonspecific abdominal symptoms: A population-based cohort study of 477,870 patients in England
Background: Identifying patients presenting with nonspecific abdominal symptoms who have underlying cancer is a challenge. Common blood tests are widely used to investigate these symptoms in primary care, but their predictive value for detecting cancer in this context is unknown. We quantify the predictive value of 19 abnormal blood test results for detecting underlying cancer in patients presenting with 2 nonspecific abdominal symptoms. Methods and findings: Using data from the UK Clinical Practice Research Datalink (CPRD) linked to the National Cancer Registry, Hospital Episode Statistics and Index of Multiple Deprivation, we conducted a population-based cohort study of patients aged ≥30 presenting to English general practice with abdominal pain or bloating between January 2007 and October 2016. Positive and negative predictive values (PPV and NPV), sensitivity, and specificity for cancer diagnosis (overall and by cancer site) were calculated for 19 abnormal blood test results co-occurring in primary care within 3 months of abdominal pain or bloating presentations. A total of 9,427/425,549 (2.2%) patients with abdominal pain and 1,148/52,321 (2.2%) with abdominal bloating were diagnosed with cancer within 12 months post-presentation. For both symptoms, in both males and females aged ≥60, the PPV for cancer exceeded the 3% risk threshold used by the UK National Institute for Health and Care Excellence for recommending urgent specialist cancer referral. Concurrent blood tests were performed in two thirds of all patients (64% with abdominal pain and 70% with bloating). In patients aged 30 to 59, several blood abnormalities updated a patient’s cancer risk to above the 3% threshold: For example, in females aged 50 to 59 with abdominal bloating, pre-blood test cancer risk of 1.6% increased to: 10% with raised ferritin, 9% with low albumin, 8% with raised platelets, 6% with raised inflammatory markers, and 4% with anaemia. Compared to risk assessment solely based on presenting symptom, age and sex, for every 1,000 patients with abdominal bloating, assessment incorporating information from blood test results would result in 63 additional urgent suspected cancer referrals and would identify 3 extra cancer patients through this route (a 16% relative increase in cancer diagnosis yield). Study limitations include reliance on completeness of coding of symptoms in primary care records and possible variation in PPVs if extrapolated to healthcare settings with higher or lower rates of blood test use. Conclusions: In patients consulting with nonspecific abdominal symptoms, the assessment of cancer risk based on symptoms, age and sex alone can be substantially enhanced by considering additional information from common blood test results. Male and female patients aged ≥60 presenting to primary care with abdominal pain or bloating warrant consideration for urgent cancer referral or investigation. Further cancer assessment should also be considered in patients aged 30 to 59 with concurrent blood test abnormalities. This approach can detect additional patients with underlying cancer through expedited referral routes and can guide decisions on specialist referrals and investigation strategies for different cancer sites.
- 30 July 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (7) , e1004426
Open AccessPredictive value of abnormal blood tests for detecting cancer in primary care patients with nonspecific abdominal symptoms: A population-based cohort study of 477,870 patients in England
Background: Identifying patients presenting with nonspecific abdominal symptoms who have underlying cancer is a challenge. Common blood tests are widely used to investigate these symptoms in primary care, but their predictive value for detecting cancer in this context is unknown. We quantify the predictive value of 19 abnormal blood test results for detecting underlying cancer in patients presenting with 2 nonspecific abdominal symptoms. Methods and findings: Using data from the UK Clinical Practice Research Datalink (CPRD) linked to the National Cancer Registry, Hospital Episode Statistics and Index of Multiple Deprivation, we conducted a population-based cohort study of patients aged ≥30 presenting to English general practice with abdominal pain or bloating between January 2007 and October 2016. Positive and negative predictive values (PPV and NPV), sensitivity, and specificity for cancer diagnosis (overall and by cancer site) were calculated for 19 abnormal blood test results co-occurring in primary care within 3 months of abdominal pain or bloating presentations. A total of 9,427/425,549 (2.2%) patients with abdominal pain and 1,148/52,321 (2.2%) with abdominal bloating were diagnosed with cancer within 12 months post-presentation. For both symptoms, in both males and females aged ≥60, the PPV for cancer exceeded the 3% risk threshold used by the UK National Institute for Health and Care Excellence for recommending urgent specialist cancer referral. Concurrent blood tests were performed in two thirds of all patients (64% with abdominal pain and 70% with bloating). In patients aged 30 to 59, several blood abnormalities updated a patient’s cancer risk to above the 3% threshold: For example, in females aged 50 to 59 with abdominal bloating, pre-blood test cancer risk of 1.6% increased to: 10% with raised ferritin, 9% with low albumin, 8% with raised platelets, 6% with raised inflammatory markers, and 4% with anaemia. Compared to risk assessment solely based on presenting symptom, age and sex, for every 1,000 patients with abdominal bloating, assessment incorporating information from blood test results would result in 63 additional urgent suspected cancer referrals and would identify 3 extra cancer patients through this route (a 16% relative increase in cancer diagnosis yield). Study limitations include reliance on completeness of coding of symptoms in primary care records and possible variation in PPVs if extrapolated to healthcare settings with higher or lower rates of blood test use. Conclusions: In patients consulting with nonspecific abdominal symptoms, the assessment of cancer risk based on symptoms, age and sex alone can be substantially enhanced by considering additional information from common blood test results. Male and female patients aged ≥60 presenting to primary care with abdominal pain or bloating warrant consideration for urgent cancer referral or investigation. Further cancer assessment should also be considered in patients aged 30 to 59 with concurrent blood test abnormalities. This approach can detect additional patients with underlying cancer through expedited referral routes and can guide decisions on specialist referrals and investigation strategies for different cancer sites.
- Open Access
- 6 December 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 130 (2) , 297-307
The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit
Background: Understanding relationships between presenting symptoms and subsequently diagnosed cancers can inform symptom awareness campaigns and investigation strategies. Methods: We used English National Cancer Diagnosis Audit 2018 data for 55,122 newly diagnosed patients, and examined the relative frequency of presenting symptoms by cancer site, and of cancer sites by presenting symptom. Results: Among 38 cancer sites (16 cancer groups), three classes were apparent: cancers with a dominant single presenting symptom (e.g. melanoma); cancers with diverse presenting symptoms (e.g. pancreatic); and cancers that are often asymptomatically detected (e.g. chronic lymphocytic leukaemia). Among 83 symptoms (13 symptom groups), two classes were apparent: symptoms chiefly relating to cancers of the same body system (e.g. certain respiratory symptoms mostly relating to respiratory cancers); and symptoms with a diverse cancer site case-mix (e.g. fatigue). The cancer site case-mix of certain symptoms varied by sex. Conclusion: We detailed associations between presenting symptoms and cancer sites in a large, representative population-based sample of cancer patients. The findings can guide choice of symptoms for inclusion in awareness campaigns, and diagnostic investigation strategies post-presentation when cancer is suspected. They can inform the updating of clinical practice recommendations for specialist referral encompassing a broader range of cancer sites per symptom.
- 6 December 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 130 (2) , 297-307
Open AccessThe presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit
Background: Understanding relationships between presenting symptoms and subsequently diagnosed cancers can inform symptom awareness campaigns and investigation strategies. Methods: We used English National Cancer Diagnosis Audit 2018 data for 55,122 newly diagnosed patients, and examined the relative frequency of presenting symptoms by cancer site, and of cancer sites by presenting symptom. Results: Among 38 cancer sites (16 cancer groups), three classes were apparent: cancers with a dominant single presenting symptom (e.g. melanoma); cancers with diverse presenting symptoms (e.g. pancreatic); and cancers that are often asymptomatically detected (e.g. chronic lymphocytic leukaemia). Among 83 symptoms (13 symptom groups), two classes were apparent: symptoms chiefly relating to cancers of the same body system (e.g. certain respiratory symptoms mostly relating to respiratory cancers); and symptoms with a diverse cancer site case-mix (e.g. fatigue). The cancer site case-mix of certain symptoms varied by sex. Conclusion: We detailed associations between presenting symptoms and cancer sites in a large, representative population-based sample of cancer patients. The findings can guide choice of symptoms for inclusion in awareness campaigns, and diagnostic investigation strategies post-presentation when cancer is suspected. They can inform the updating of clinical practice recommendations for specialist referral encompassing a broader range of cancer sites per symptom.
- Open Access
- 9 November 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 87, 102484
Stage-specific risk of colon and rectal cancer in patients presenting with rectal bleeding or change in bowel habit in primary care: A population-based cohort study
- 9 November 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 87, 102484
Open AccessStage-specific risk of colon and rectal cancer in patients presenting with rectal bleeding or change in bowel habit in primary care: A population-based cohort study